Clinical trials
Completed Phase 3 Osteoarthritis, Knee trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
145 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 5 |
| 2003 | 8 |
| 2004 | 6 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 6 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 8 |
| 2015 | 8 |
| 2016 | 7 |
| 2017 | 12 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 145 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis | 7 |
| Pfizer | 5 |
| Ampio Pharmaceuticals. Inc. | 4 |
| Anika Therapeutics, Inc. | 4 |
| Eli Lilly and Company | 4 |
| Johnson & Johnson Consumer and Personal Products Worldwide | 4 |
| Labopharm Inc. | 4 |
| Pacira Pharmaceuticals, Inc | 4 |
| Biosplice Therapeutics, Inc. | 3 |
| Centrexion Therapeutics | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Osteoarthritis, Knee | 145 |
| Osteoarthritis | 56 |
| Pain | 22 |
| Osteoarthritis, Hip | 16 |
| Arthritis | 4 |
| Chronic Pain | 4 |
| Joint Diseases | 4 |
| Musculoskeletal Diseases | 3 |
| Postoperative Pain | 3 |
| Agnosia | 2 |
Trials
Showing 1 to 25 of 145. Each trial links to its page on Pharma Observatory.
45 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.